⌘K
Loading ticker…
As of 2026-08-24, Opus Genetics, Inc. Common Stock (IRD) has a 3-month relative strength percentile of 37 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 73. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.1%, relative volume 1.00×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
IRD is held by 3 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $9M notional. Top 3 carry $11M.
Held by 3 ETFs · $11M across latest filings · largest weight 0.01% (BSVO).
Top 3 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $9M | — |
| VXFVanguard Extended Market ETF | 0.00% | $2M | — |
| BSVO | 0.01% | $191K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | IRD Jan avg: 4.10% median: 4.10% win: 50% σ: 15.31% n: 2 2024-10-25 → 2026-07-31 | IRD Feb avg: 36.44% median: 36.44% win: 50% σ: 61.73% n: 2 2024-10-25 → 2026-07-31 | IRD Mar avg: 2.35% median: 2.35% win: 50% σ: 9.94% n: 2 2024-10-25 → 2026-07-31 | IRD Apr avg: 4.53% median: 4.53% win: 50% σ: 10.99% n: 2 2024-10-25 → 2026-07-31 | IRD May avg: -5.00% median: -5.00% win: 50% σ: 13.69% n: 2 2024-10-25 → 2026-07-31 | IRD Jun avg: -5.50% median: -5.50% win: 0% σ: 0.33% n: 2 2024-10-25 → 2026-07-31 | IRD Jul avg: 4.04% median: 4.04% win: 50% σ: 19.48% n: 2 2024-10-25 → 2026-07-31 | IRD Aug avg: 9.91% median: 9.91% win: 100% σ: 0.00% n: 1 2024-10-25 → 2026-07-31 (current) | IRD Sep avg: 35.25% median: 35.25% win: 100% σ: 0.00% n: 1 2024-10-25 → 2026-07-31 | IRD Oct avg: 22.79% median: 22.79% win: 100% σ: 23.47% n: 2 2024-10-25 → 2026-07-31 | IRD Nov avg: -7.45% median: -7.45% win: 0% σ: 0.08% n: 2 2024-10-25 → 2026-07-31 | IRD Dec avg: 0.79% median: 0.79% win: 50% σ: 9.08% n: 2 2024-10-25 → 2026-07-31 |